TearSolutions, Inc.

TearSolutions, Inc. , based in the US, focuses on developing innovative peptide therapies to address ocular surface diseases, particularly Dry Eye Disease, enhancing the quality of life for affected patients. TearSolutions, Inc. specializes in developing therapies for ocular surface diseases, notably Dry Eye Disease.

Founded in 2013 in Charlottesville, US, by Gordon Laurie and Mark Logan, the company has secured USD 12. 71 mn in Series B funding as of September 2024, bringing its total raised to USD 12. 71 mn and its valuation to USD 50. 131 mn.

Anil Asrani serves as CEO. The company has completed 4 deals to date. TearSolutions, Inc. specializes in the development of Lacripep™, a proprietary peptide therapy aimed at treating ocular surface diseases, especially Dry Eye Disease.

Lacripep is derived from the Lacritin protein, functioning as a topical therapy to stabilize tear film and enhance corneal health, particularly for patients with primary Sjögren’s Syndrome. The therapy primarily targets individuals diagnosed with Dry Eye Disease in the US and globally, focusing on clinical practices and academic institutions in ophthalmology and optometry. TearSolutions generates revenue through clinical trials and potential commercialization of Lacripep. Its business model involves partnerships with private and academic clinics participating in clinical trials to validate Lacripep's efficacy.

These arrangements typically include funding for research and development and performance milestones, although specific pricing structures for the product remain undisclosed due to ongoing investigations and lack of FDA approval. In September 2024, TearSolutions, Inc. raised USD 12. 71 mn in Series B funding, which will be utilized to enhance efforts in addressing rare corneal diseases.

The company is focused on strengthening its product development initiatives and exploring opportunities for expansion into new markets, particularly in regions with high prevalence of ocular surface diseases.